By touching $1.48 share price a new yearly low was recored by the Avadel Pharmaceuticals plc (NASDAQ:AVDL). The yearly low was reported on Mar, 23 by Barchart.com. The company has $54.78 million MC. At our $1.39 PT, the company worth will be $3.29M less.

AVDL reached $1.48 during the last trading session after $0.09 change.Avadel Pharmaceuticals plc is downtrending after having declined 75.66% since March 23, 2018. AVDL has 188,057 volume or 22.63% up from normal. The stock underperformed the S&P500 by 80.03%.

For more Avadel Pharmaceuticals plc (NASDAQ:AVDL) news posted recently go to: Nasdaq.com, Globenewswire.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Jazz Pharmaceuticals’ Sleep Drug NDA Awaits FDA Decision – Nasdaq” posted on March 20, 2019, “Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results – GlobeNewswire” on March 07, 2019, “Avadel down 24% premarket on restructuring – Seeking Alpha” with a publish date: February 07, 2019, “Avadel Pharma Q3 revenues down 50% – Seeking Alpha” and the last “European ADRs Move Higher in Monday Trading – Nasdaq” with publication date: March 18, 2019.

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland.The firm is worth $54.78 million. The company's owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs.Currently it has negative earnings. The Company’s lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection.